Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 46.6% from a year ago

Cash & equivalents stood at $24.41M at the end of Q1 FY2026, down 46.6% from a year earlier and down 39.8% from the prior quarter. Over 3 fiscal years it compounded at +18.4% a year.

Context

  • Cash & equivalents amounted to 4.8% of total assets at the end of Q1 FY2026, down 21.1 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -46.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.41M-39.8% QoQ
Last fiscal yearDec 2025
$40.58M-28.5% YoY
Year agoMar 2025
$45.73M-46.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-46.6%——
1 year-28.5%——
3-year CAGR+18.4%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
40.58M USD
Year-over-year change
-28.5%
4-year CAGR
+21.1%

Cash & Equivalents vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's Mar 2026 cash & equivalents of $24.41M is the 8th highest of the 10 companies compared; the peer median is $61.27M.
  • Its year-over-year change of -46.6% is the 8th highest of 10, against a peer median of +19.5%.
  • Cash & equivalents amounts to 4.8% of total assets for RIGL, versus a peer median of 18.6%.
RIGL Competitors Peer median
Cash & Equivalents for RIGL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NRIXNurix Therapeutics, Inc.Aug 2026$720.24M +818.2%+56.5%60.3%
EXELExelixis, Inc.Jul 2026$281.45M +71.2%-1.3%11.3%
VSTMVerastem, Inc.Mar 2026$165.55M +40.8%+39.9%72.7%
CGEMCullinan Therapeutics, Inc.Mar 2026$75.08M -2.1%-17.3%18.6%
CCCCC4 Therapeutics, Inc.Mar 2026$61.27M +19.5%+35.9%18.6%
MREOMereo BioPharma Group plcMar 2026$36.22M -42.0%-15.6%89.2%
ALXOALX Oncology Holdings Inc.Mar 2026$32.28M +56.6%-30.5%18.1%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$24.41M -46.6%+18.4%4.8%
ANLAdlai Nortye Ltd.Dec 2025$23.79M -60.9%-17.8%69.1%
CRDFCardiff Oncology, Inc.Mar 2026$8.54M -64.5%+2.2%17.4%
Peer median (excluding RIGL) $61.27M+19.5%-1.3%18.6%

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents18.89M24.46M32.79M56.75M40.58M
Short-term Investments106.08M33.75M24.15M20.58M114.38M
Net Receivables15.47M40.32M30.55M41.62M51.76M
Inventory6.62M9.12M5.52M6M11.51M
Other Current Assets08.26M6.26M10.17M21.94M
Total Current Assets154.47M115.9M99.27M135.1M240.17M
Property, Plant & Equipment (Net)11.89M2.79M1.03M338K920K
Goodwill00000
Intangible Assets014.95M13.88M27.1M24.75M
Long-term Investments00000
Tax Assets0000245.85M
Other Non-current Assets974K640K3.06M1.44M1.91M
Total Non-current Assets12.86M18.38M17.96M28.87M273.43M
Total Assets167.33M134.28M117.23M163.98M513.59M
Account Payables3.8M22.51M7.14M3.34M7.19M
Short-term Debt007.23M7.27M30.43M
Tax Payables00000
Deferred Revenue10.51M13.51M17.04M27.8M1.36M
Other Current Liabilities24.2M13.86M12.32M10.14M48.35M
Total Current Liabilities63.55M65.21M53.27M63.3M99.24M
Long-term Debt19.91M39.45M52.37M52.41M22.88M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities52.73M42.26M39.94M44.98M0
Total Non-current Liabilities73.4M82.68M92.6M97.39M22.88M
Total Liabilities136.95M147.9M145.87M160.69M122.11M
Common Stock172K174K17K18K18K
Retained Earnings(1.32B)(1.38B)(1.41B)(1.39B)(1.02B)
Accumulated OCI(102K)(153K)8K10K181K
Other Stockholders Equity00000
Minority Interest00000
Total Equity30.37M(13.62M)(28.64M)3.29M391.48M
Total Debt30.57M41.55M60.58M59.97M53.3M
Net Debt11.68M17.09M27.79M3.22M12.72M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.